VALPROATO DI SODIO NEL TRATTAMENTO DELLA EPILESSIA ASSOCIATA ALLA PORFIRIA ACUTA INTERMITTENTE

Translated title of the contribution: Valproate sodium in treatment of epilepsy associated with acute intermittent porphyria

R. Michelucci, A. Baruzzi, C. A. Tassinari

Research output: Contribution to journalArticle

Abstract

At 21 yr old white male had both an intermittent acute porphyria (IAP) and a long standing post-traumatic focal epilepsy. Most anticonvulsivant drugs apparently adversely affected both the clinical and biomedical parameters of IAP. Significant clinical improvement of the porphyria followed withdrawal of phenobarbital (PB) and carbamazepine (CBZ). Sodium valproate (VPA) appeared to be a safe drug in IAP and approximately as effective as PB for seizure control in our patient. Moreover, while the apparent plasma half life (T 1/2) of CBZ and PB were prolonged in our patient, VPA T 1/2 did not differ from those reported in the literature. It was apparent, therfore, also in regard to our findings with CBZ and VPA elimination, that VPA could be a reasonable solution to the therapeutic problem of a chronic seizure control in IAP.

Translated title of the contributionValproate sodium in treatment of epilepsy associated with acute intermittent porphyria
Original languageItalian
Pages (from-to)309-314
Number of pages6
JournalRivista di Neurobiologia
Volume10
Issue number2
Publication statusPublished - 1981

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Valproate sodium in treatment of epilepsy associated with acute intermittent porphyria'. Together they form a unique fingerprint.

  • Cite this